BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanda M, Sugimoto H, Nomoto S, Oya H, Hibino S, Shimizu D, Takami H, Hashimoto R, Okamura Y, Yamada S. Bcell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. Int J Oncol. 2015;46:641-648. [PMID: 25405901 DOI: 10.3892/ijo.2014.2762] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Kanda M, Shimizu D, Sueoka S, Nomoto S, Oya H, Takami H, Ezaka K, Hashimoto R, Tanaka Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Prognostic relevance of SAMSN1 expression in gastric cancer. Oncol Lett 2016;12:4708-16. [PMID: 28105178 DOI: 10.3892/ol.2016.5233] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kaur H, Bhalla S, Raghava GPS. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles. PLoS One 2019;14:e0221476. [PMID: 31490960 DOI: 10.1371/journal.pone.0221476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
3 Shimizu D, Kanda M, Sugimoto H, Shibata M, Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol 2017;50:381-6. [PMID: 28101581 DOI: 10.3892/ijo.2017.3833] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
4 Xu Y, Zhang G, Zou C, Gong Z, Wang S, Liu J, Ma G, Liu X, Zhang W, Jiang P. Long noncoding RNA DGCR5 suppresses gastric cancer progression by acting as a competing endogenous RNA of PTEN and BTG1. J Cell Physiol 2019;234:11999-2010. [PMID: 30515803 DOI: 10.1002/jcp.27861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
5 Kanda M, Shimizu D, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667-13679. [PMID: 26872374 DOI: 10.18632/oncotarget.7269] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
6 Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015;21:9838-9852. [PMID: 26379391 DOI: 10.3748/wjg.v21.i34.9838] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 61] [Article Influence: 12.8] [Reference Citation Analysis]
7 Kanda M, Murotani K, Sugimoto H, Miwa T, Umeda S, Suenaga M, Hayashi M, Hattori N, Tanaka C, Kobayashi D, Yamada S, Fujiwara M, Kodera Y. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget 2017;8:71070-9. [PMID: 29050343 DOI: 10.18632/oncotarget.20369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Wang JZ, Zhang YH, Guo XH, Zhang HY, Zhang Y. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. Int Immunopharmacol 2016;36:73-85. [PMID: 27111515 DOI: 10.1016/j.intimp.2016.04.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
9 Guo FF, Cui JW. The Role of Tumor-Infiltrating B Cells in Tumor Immunity. J Oncol 2019;2019:2592419. [PMID: 31662750 DOI: 10.1155/2019/2592419] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
10 Shimizu D, Kanda M, Sugimoto H, Sueoka S, Takami H, Ezaka K, Tanaka Y, Hashimoto R, Okamura Y, Iwata N, Tanaka C, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncol Lett 2016;11:1847-54. [PMID: 26998088 DOI: 10.3892/ol.2016.4120] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
11 Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, Iwata N, Niwa Y, Yamada S, Fujii T, Sugimoto H, Murotani K, Fujiwara M, Kodera Y. Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. Ann Surg. 2018;267:495-503. [PMID: 28026832 DOI: 10.1097/sla.0000000000002096] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
12 Zhang Y, Wang S, Xiao J, Zhou H. Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinoma. Biosci Rep. 2019;39. [PMID: 30705088 DOI: 10.1042/bsr20181845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Zheng HC, Li J, Shen DF, Yang XF, Zhao S, Wu YZ, Takano Y, Sun HZ, Su RJ, Luo JS, Gou WF. BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy. Oncotarget 2015;6:19685-705. [PMID: 26050197 DOI: 10.18632/oncotarget.4081] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
14 Kanda M, Shimizu D, Fujii T, Sueoka S, Tanaka Y, Ezaka K, Takami H, Tanaka H, Hashimoto R, Iwata N. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138:721-730. [PMID: 26270236 DOI: 10.1002/ijc.29803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
15 Li E, Han K, Zhou X. microRNA-27a-3p Down-regulation Inhibits Malignant Biological Behaviors of Ovarian Cancer by Targeting BTG1. Open Med (Wars) 2019;14:577-85. [PMID: 31410369 DOI: 10.1515/med-2019-0065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kim JY, Do SI, Bae GE, Kim HS. B-cell translocation gene 1 is downregulated by promoter methylation in ovarian carcinoma. J Cancer 2017;8:2669-75. [PMID: 28928854 DOI: 10.7150/jca.21037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhao S, Chen SR, Yang XF, Shen DF, Takano Y, Su RJ, Zheng HC. BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers. Oncotarget. 2017;8:7502-7520. [PMID: 27447746 DOI: 10.18632/oncotarget.10649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
18 Chen XQ, Meng FQ, Xiong H, Wang YL, Tang WH, Zou YM. Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis. Curr Med Sci 2020;40:85-94. [PMID: 32166669 DOI: 10.1007/s11596-020-2150-z] [Reference Citation Analysis]
19 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
20 Yuniati L, Scheijen B, van der Meer LT, van Leeuwen FN. Tumor suppressors BTG1 and BTG2: Beyond growth control. J Cell Physiol 2019;234:5379-89. [PMID: 30350856 DOI: 10.1002/jcp.27407] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
21 Li Y, Huo J, He J, Zhang Y, Ma X. BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma. Cancer Cell Int 2020;20:490. [PMID: 33041670 DOI: 10.1186/s12935-020-01591-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol. 2016;22:6829-6840. [PMID: 27570420 DOI: 10.3748/wjg.v22.i30.6829] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
23 Zhou X, Yuan Y, Teng F, Li K, Luo S, Zhang P, Liu D, Zhang H, Zhang J. Obesity-induced upregulation of microRNA-183-5p promotes hepatic triglyceride accumulation by targeting the B-cell translocation gene 1. Life Sci 2021;268:119011. [PMID: 33421522 DOI: 10.1016/j.lfs.2020.119011] [Reference Citation Analysis]
24 Zhang SQ, Yang Z, Cai XL, Zhao M, Sun MM, Li J, Feng GX, Feng JY, Ye LH, Niu JQ, Zhang XD. miR-511 promotes the proliferation of human hepatoma cells by targeting the 3'UTR of B cell translocation gene 1 (BTG1) mRNA. Acta Pharmacol Sin 2017;38:1161-70. [PMID: 28603285 DOI: 10.1038/aps.2017.62] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015;9:1549-1560. [PMID: 26414453 DOI: 10.1586/17474124.2015.1094373] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
26 Xiao F, Deng J, Guo Y, Niu Y, Yuan F, Yu J, Chen S, Guo F. BTG1 ameliorates liver steatosis by decreasing stearoyl-CoA desaturase 1 (SCD1) abundance and altering hepatic lipid metabolism. Sci Signal 2016;9:ra50. [PMID: 27188441 DOI: 10.1126/scisignal.aad8581] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
27 Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y. Integrated multigene expression panel to prognosticate patients with gastric cancer. Oncotarget 2018;9:18775-85. [PMID: 29721160 DOI: 10.18632/oncotarget.24661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sueoka S, Kanda M, Sugimoto H, Shimizu D, Nomoto S, Oya H, Takami H, Ezaka K, Hashimoto R, Tanaka Y, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Fujiwara M, Kodera Y. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Ann Surg Oncol 2015;22:1453-60. [DOI: 10.1245/s10434-015-4524-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
29 Ezaka K, Kanda M, Sugimoto H, Shimizu D, Oya H, Nomoto S, Sueoka S, Tanaka Y, Takami H, Hashimoto R. Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Ann Surg Oncol. 2015;22 Suppl 3:S1499-S1507. [PMID: 26122373 DOI: 10.1245/s10434-015-4695-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]